Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial

被引：0
|
作者：
Baselga, J. [1 ]
Campone, M. [2 ]
Sahmoud, T. [3 ]
Piccart, M. [4 ]
Burris, H. [5 ]
Rugo, H. [6 ]
Noguchi, S. [7 ]
Gnant, M. [8 ]
Mukhopadhyay, P. [9 ]
Hortobagyi, G. [10 ]
机构：
[1] Massachusetts Gen Hosp, Dept Oncol, Boston, MA 02114 USA
[2] Ctr Reg Rene Gauducheau, Dept Med Oncol, St Herblain, France
[3] Novartis Pharmaceut, Global Oncol Dev, Florham Pk, NJ USA
[4] Inst Jules Bordet, Dept Med, B-1000 Brussels, Belgium
[5] Sarah Cannon Res Inst, Drug Dev Program, Nashville, TN USA
[6] Univ Calif San Francisco, Dept Med Hematol Oncol, San Francisco, CA 94143 USA
[7] Osaka Univ, Dept Breast & Endocrine Surg, Osaka, Japan
[8] Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, Vienna, Austria
[9] Novartis Pharmaceut, Oncol BDM, Florham Pk, NJ USA
[10] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70108-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9LBA
引用
收藏
页码：6 / +
页数：3
相关论文
共 50 条
  • [1] BOLERO-2: EVEROLIMUS IN COMBINATION WITH EXEMESTANE IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE ADVANCED BREAST CANCER REFRACTORY TO LETROZOLE OR ANASTROZOLE
    Campone, Mario
    Piccart, Martine
    Pritchard, Kathleen I.
    Xu, Cindy
    Gnant, Michael
    Neven, Patrick
    Pistilli, Barbara
    Shtivelband, Mikhail
    Provencher, Louise
    Masuda, Norikazu
    El-Hashimy, Mona
    Vittori, Luc
    Sahmoud, Tarek
    Baselga, Jose
    Hortobagyi, Gabriel N.
    BREAST, 2011, 20 : S30 - S30
  • [2] Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial
    Baselga, J.
    Campone, M.
    Piccart-Gebhart, M. J.
    Burris, H. A.
    Rugo, H. S.
    Noguchi, S.
    Gnant, M.
    Pritchard, K. I.
    Lebrun, F.
    Beck, J. T.
    Ito, Y.
    Yardley, D. A.
    Deleu, I.
    Perez, A.
    Bachelot, T. D.
    Vittori, L.
    Mukhopadhyay, P.
    Weber, D.
    Sahmoud, T.
    Hortobagyi, G. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial
    Rugo, H.
    Pritchard, K. I.
    Gnant, M.
    Noguchi, S.
    Piccart, M.
    Hortobagyi, G. N.
    Burris, H. A.
    Bauly, H.
    Sahmoud, T.
    Baselga, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S116 - S116
  • [4] Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.
    Piccart-Gebhart, Martine J.
    Noguchi, Shinzaburo
    Pritchard, Kathleen I.
    Burris, Howard A.
    Rugo, Hope S.
    Gnant, Michael
    Hortobagyi, Gabriel N.
    Melichar, Bohuslav
    Petrakova, Katarina
    Arena, Francis P.
    Xu, Cindy
    Cahana, Ayelet
    Taran, Tanya
    Sahmoud, Tarek
    Lebwohl, David Edward
    Campone, Mario
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.
    Arena, Francis P.
    Noguchi, Shinzaburo
    Pritchard, Kathleen I.
    Burris, Howard A.
    Rugo, Hope S.
    Gnant, Michael
    Hortobagyi, Gabriel N.
    Latini, Luciano
    Yardley, Denise Aysel
    Melichar, Bohuslav
    Petrakova, Katarina
    Harb, Wael
    Feng, Wentao
    Cahana, Ayelet
    Taran, Tanya
    Campone, Mario
    Baselga, Jose
    Sahmoud, Tarek
    Lebwohl, David Edward
    Piccart-Gebhart, Martine J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [6] UPDATED RESULTS OF THE BOLERO-2 PHASE III TRIAL EVALUATING EVEROLIMUS (EVE) FOR POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER (ABC)
    Rugo, H.
    Piccart, M.
    Hortobagyi, G.
    Noguchi, S.
    Gnant, M.
    Campone, M.
    Bauly, H.
    Mukhopadhyay, P.
    Sahmoud, T.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 46 - 46
  • [7] Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase Ill Trial.
    Hortobagyi, G. N.
    Piccart, M.
    Rugo, H.
    Burris, H.
    Campone, M.
    Noguchi, S.
    Gnant, M.
    Pritchard, K. I.
    Vittori, L.
    Mukhopadhyay, P.
    Sahmoud, T.
    Lebwohl, D.
    Baselga, J.
    CANCER RESEARCH, 2011, 71
  • [8] Everolimus Added to Exemestane Reduced Bone Markers in Postmenopausal Women with Advanced Breast Cancer (ABC): the BOLERO-2 Trial
    Gnant, M.
    Hortobagyi, G. N.
    Rugo, H.
    Burris, H. A.
    Noguchi, S.
    Pritchard, K. I.
    Baselga, J.
    Sahmoud, T.
    Bauly, H.
    Piccart, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S43 - S43
  • [9] The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
    Beaver, Julia A.
    Park, Ben H.
    FUTURE ONCOLOGY, 2012, 8 (06) : 651 - 657
  • [10] Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial
    Gnant, M.
    Hortobagyi, G. N.
    Rugo, H.
    Burris, H. A.
    Noguchi, S.
    Pritchard, K. I.
    Baselga, J.
    Sahmoud, T.
    Bauly, H.
    Piccart, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S2 - S2
12345